(Q37741779)

22 August 2017

1 reference

title

Role of triglyceride-rich lipoproteins in diabetic nephropathy (English)

1 reference

22 August 2017

1 reference

1 reference

John C Rutledge

1

1 reference

22 August 2017

Kit F Ng

series ordinal

2

1 reference

22 August 2017

Hnin H Aung

series ordinal

3

1 reference

22 August 2017

Dennis W Wilson

series ordinal

4

1 reference

22 August 2017

language of work or name

English

0 references

publication date

4 May 2010

1 reference

Nature Reviews Nephrology

22 August 2017

published in

1 reference

22 August 2017

volume

6

1 reference

22 August 2017

issue

6

1 reference

22 August 2017

page(s)

361-370

1 reference

Angiotensin II injures the arterial wall causing increased aortic stiffening in apolipoprotein E-deficient mice

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

The progression of renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Accumulation of triglyceride-rich lipoprotein in subjects with abdominal obesity: the biguanides and the prevention of the risk of obesity (BIGPRO) 1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Oxidized lipoproteins degrade the endothelial surface layer : implications for platelet-endothelial cell adhesion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Microvascular complications of diabetes mellitus: renal protection accompanies cardiovascular protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Update in podocyte biology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Nephrin and endothelial injury.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Involvement of glomerular SREBP-1c in diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Major role for ACE-independent intrarenal ANG II formation in type II diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Effects of increased renal tubular vascular endothelial growth factor (VEGF) on fibrosis, cyst formation, and glomerular disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Glomerular 20-HETE, EETs, and TGF-beta1 in diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Proinsulin C-peptide reduces diabetes-induced glomerular hyperfiltration via efferent arteriole dilation and inhibition of tubular sodium reabsorption

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Human mesangial cells express inducible macrophage scavenger receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Predictors of microalbuminuria in individuals with IDDM. Pittsburgh Epidemiology of Diabetes Complications Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients: a 10-year prospective observational study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Prevalence of complications in IDDM by sex and duration. Pittsburgh Epidemiology of Diabetes Complications Study II

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Albuminuria reflects widespread vascular damage. The Steno hypothesis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Atherogenic lipoprotein changes in diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Decreased release of lipoprotein lipase is associated with vascular endothelial damage in NIDDM patients with microalbuminuria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Studies of renal injury III: lipid-induced nephropathy in type II diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year follow-up of the Paris Prospective Study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Dyslipoproteinemia in diabetic renal failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Atherogenic lipoproteins and diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Very low-density lipoprotein-apoprotein CI is increased in diabetic nephropathy: comparison with apoprotein CIII.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Lipoproteins in the DCCT/EDIC cohort: associations with diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

High-Density Lipoproteins Inhibit Cytokine-Induced Expression of Endothelial Cell Adhesion Molecules

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Systemic and vascular inflammation is elevated in early IgA and type 1 diabetic nephropathies and relates to vascular disease risk factors and renal function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

A macrophage receptor for apolipoprotein B48: cloning, expression, and atherosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

31 March 2020

Chylomicron metabolism

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Remarkable increase of apolipoprotein B48 level in diabetic patients with end-stage renal disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Lipoprotein abnormalities in diabetic nephropathy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Changes in the plasma lipoprotein distribution of apolipoproteins C-II, C-III1, C-III2 and apolipoprotein B after heparin-induced lipolysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Apolipoprotein E deficiency in mice: gene replacement and prevention of atherosclerosis using adenovirus vectors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensit

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Hyperglycemia, lipoprotein glycation, and vascular disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Clinical review: The role of advanced glycation end products in progression and complications of diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Apolipoprotein E genetic polymorphism, remnant lipoproteins, and nephropathy in type 2 diabetic patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Lack of relationship in long-term type 1 diabetic patients between diabetic nephropathy and polymorphisms in apolipoprotein epsilon, lipoprotein lipase and cholesteryl ester transfer protein. Genétique de la Nephropathie Diabétique Study Group. Donn

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Role of sterol regulatory element-binding protein 1 in regulation of renal lipid metabolism and glomerulosclerosis in diabetes mellitus.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Increased plasma apolipoprotein(a) levels in IDDM patients with microalbuminuria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Relationship of progressively increasing albuminuria to apoprotein(a) and blood pressure in type 2 (non-insulin-dependent) and type 1 (insulin-dependent) diabetic patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

High levels of inflammatory biomarkers are associated with increased allele-specific apolipoprotein(a) levels in African-Americans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Association between plasma oxidized low-density lipoprotein and diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Lipid-lowering therapy in patients with renal disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Lipids and progressive renal disease: the cardio-renal link

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Statins and progressive renal disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Atorvastatin affects low density lipoprotein and non-high density lipoprotein cholesterol relations with apolipoprotein B in type 2 diabetes mellitus: modification by triglycerides and cholesteryl ester transfer protein.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Effect of lipid reduction on the progression of renal disease: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Ev

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Peroxisome proliferator-activated receptor-alpha activator fenofibrate prevents high-fat diet-induced renal lipotoxicity in spontaneously hypertensive rats.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Management of dyslipidemias in patients with diabetes and chronic kidney disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Dyslipidemia and the progression of renal disease in chronic renal failure patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Pravastatin modulates early diabetic nephropathy in an experimental model of diabetic renal disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Lipotoxic and inflammatory phenotypes in rats with uncontrolled metabolic syndrome and nephropathy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Hyperglycemia and hyperlipidemia act synergistically to induce renal disease in LDL receptor-deficient BALB mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Lipolysis products from triglyceride-rich lipoproteins increase endothelial permeability, perturb zonula occludens-1 and F-actin, and induce apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Dietary fish oil reduces progression of established renal disease in (NZB x NZW)F1 mice and delays renal disease in BXSB and MRL/1 strains

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Omega-3 fatty acid supplementation attenuates oxidative stress, inflammation, and tubulointerstitial fibrosis in the remnant kidney

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Renal mass reduction results in accumulation of lipids and dysregulation of lipid regulatory proteins in the remnant kidney

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Alterations in fatty acid utilization and an impaired antioxidant defense mechanism are early events in podocyte injury: a proteomic analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Different roles for TGF-beta and VEGF in the pathogenesis of the cardinal features of diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Mediators of diabetic renal disease: the case for tgf-Beta as the major mediator

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Oxidized LDL stimulates the expression of TGF-beta and fibronectin in human glomerular epithelial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Localization of transforming growth factor-beta and latent transforming growth factor-beta binding protein in rat kidney

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Integrins in kidney development, function, and disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Thrombospondin 1 mediates angiotensin II induction of TGF-beta activation by cardiac and renal cells under both high and low glucose conditions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Making sense of latent TGFbeta activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Triglyceride-rich lipoprotein lipolysis increases aggregation of endothelial cell membrane microdomains and produces reactive oxygen species

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Nox4 NAD(P)H oxidase mediates hypertrophy and fibronectin expression in the diabetic kidney

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Diabetic nephropathy and transforming growth factor-beta: transforming our view of glomerulosclerosis and fibrosis build-up

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

The key role of the transforming growth factor-beta system in the pathogenesis of diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Smad pathway is activated in the diabetic mouse kidney and Smad3 mediates TGF-beta-induced fibronectin in mesangial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

The endothelial glycocalyx protects against myocardial edema

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Endothelial cell glycocalyx modulates immobilization of leukocytes at the endothelial surface

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

NAD(P)H oxidase mediates TGF-beta1-induced activation of kidney myofibroblasts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

The endothelial glycocalyx: a potential barrier between health and vascular disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Morphological and functional evidence for an important role of the endothelial cell glycocalyx in the glomerular barrier

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Endothelial glycocalyx damage coincides with microalbuminuria in type 1 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Glomerular endothelial glycocalyx constitutes a barrier to protein permeability

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Fatty acids from very low-density lipoprotein lipolysis products induce lipid droplet accumulation in human monocytes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Native and oxidized low-density lipoproteins enhance superoxide production from diabetic rat glomeruli

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Lipids and diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Role of advanced glycation end products in diabetic nephropathy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

RAGE and the pathogenesis of chronic kidney disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Accumulation of advanced oxidation protein products induces podocyte apoptosis and deletion through NADPH-dependent mechanisms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Effect of reactive oxygen species on endothelin-1 production by human mesangial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Cellular lipid metabolism and the role of lipids in progressive renal disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

The role of oxidatively modified lipoproteins in lipid nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Regression of microalbuminuria in type 1 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.59

Distinct patterns of lipoproteins with apoB defined by presence of apoE or apoC-III in hypercholesterolemia and hypertriglyceridemia.

31 March 2020

1 reference

12 December 2020

Dynamics of apolipoprotein E metabolism in humans.

1 reference

12 December 2020

Potential influence of lipids in diabetic nephropathy: insights from experimental data and clinical studies.

1 reference

12 December 2020

Predictors of the development of microalbuminuria in patients with Type 1 diabetes mellitus: a seven-year prospective study. The Microalbuminuria Collaborative Study Group

1 reference

12 December 2020

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRNEPH.2010.59

1 reference

22 August 2017

1 reference